Drug Trial Radar · NCT05622708
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
240
Actual
Start
Mar 28, 2023
Primary completion
Feb 8, 2028
Study completion Apr 4, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with Non-radiographic axial spondyloarthritis, (nr-axSpA) who have achieved remission. Remission is defined as Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP) Inactive Disease (ID) response (ASDAS-CRP \< 1.3). Maintenance of remission on continued secukinumab treatment will be evaluated compared to placebo using a randomized withdrawal design. The primary outcome measure for this study is the proportion of participants remaining flare-free at Week 120.
Conditions
- Non-radiographic Axial Spondyloarthritis
Interventions
SecukinumabDrug
Treatment Period 1: Open-label secukinumab 150 mg PFS s.c. at baseline, Weeks 1, 2, 3 and 4 followed by administration every four weeks up to Week 52.
PlaceboDrug
Treatment Period 2: Double-blind placebo PFS s.c. every 4 weeks from Week 56 to Week 116.
SecukinumabDrug
Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116. Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of participants remaining flare-free during Treatment Period 2Time frame: Week 120
Locations
61 sites in 18 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Bruges, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Mons, Belgium
Novartis Investigative Site
Genk, Belgium, Belgium
Novartis Investigative Site
Juiz de Fora, Minas Gerais, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
Bogota, Cundinamarca, Colombia
Novartis Investigative Site
Bogota, Cundinamarca, Colombia
Novartis Investigative Site
Chía, Cundinamarca, Colombia
Novartis Investigative Site
Bucaramanga, Santander Department, Colombia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Uherské Hradiště, Czechia
Novartis Investigative Site
Chambray-lès-Tours, France
Novartis Investigative Site
Le Mans, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Bad Doberan, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Herne, Germany
Novartis Investigative Site
Ratingen, Germany
Novartis Investigative Site
Kistarcsa, Hungary
Novartis Investigative Site
Miskolc, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Veszprém, Hungary
Novartis Investigative Site
Székesfehérvár, Fejér, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Kfar Saba, Israel
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Torino, TO, Italy
Novartis Investigative Site
Negrar, VR, Italy
Novartis Investigative Site
Verona, VR, Italy
Novartis Investigative Site
Kuala Lumpur, Malaysia
Novartis Investigative Site
Chihuahua City, Chihuahua, Mexico
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.